+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Digital Biomarker Market Outlook 2030

  • ID: 5401662
  • Report
  • June 2021
  • Region: Global
  • 401 Pages
  • Research Nester Pvt. Ltd

FEATURED COMPANIES

  • ActiGraph LLC
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd
  • Happify Inc.
  • IXICO plc
  • Koninklijke Philips N.V.

Digital biomarkers are consumer generated physiological and behavioral measures that are collected through connected digital devices. The collected data is then used to explain, influence or predict health related outcomes of an individual. The global digital biomarker market is anticipated to grow with a CAGR of 41.22% during the forecast period, i.e., 2020-2030. Factors such as the growing adoption of mobile health applications, increasing number of internet users, growing adoption of smartphone worldwide, and the rise in awareness amongst individuals for maintaining a good health, are anticipated to drive the market growth. The market garnered a revenue of around USD 1040 Million in the year 2019 and is further projected to reach over USD 46000 Million by the end of 2030.



The global digital biomarker market is segmented on the basis of numerous segments, which include segmentation by system component, therapeutic area, development status, end users, and by region. On the basis of system component, the market is segmented into data collection tools and data integration systems, out of which, the data integration systems segment is expected to grow with the highest CAGR of about 42% during the forecast period. The market is also segmented on the basis of therapeutic area into cardiovascular diseases, neurodegenerative disorders, sleep & movement diseases, psychiatric disorders, chronic pain, gastrointestinal diseases, diabetes, respiratory conditions, and others, out of which, the neurodegenerative disorders segment is expected to grab the largest market revenue of over USD 11800 Million by the end of 2030.



On the basis of regional analysis, the market is segmented into North America, Asia Pacific, Europe, South America, and Middle East & Africa, out of which, the market in North America is expected to leading market share throughout the forecast period and further garner a market revenue of close to USD 21 Million by 2030.



Some of the prominent industry leaders in the global digital biomarker market that are included in our report are ActiGraph LLC, Akili Interactive Labs, Inc., AliveCor, Inc., Altoida, Inc., Biogen Inc., ConnectedLife Health Pte Ltd, Cambridge Cognition Ltd, Evidation Health, Inc., Fitbit, Inc., Happify, Inc., Human API, GlaxoSmithKline plc, Huma, IXICO plc, Kinsa Inc., Koneksa, Medical Care Corporation, Mindstrong Health, Koninklijke Philips N.V., Neurotrack Technologies, Inc., Novartis AG, ResMed, F. Hoffmann-La Roche Ltd, Winterlight Labs, Verily Life Sciences LLC, and others.


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ActiGraph LLC
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd
  • Happify Inc.
  • IXICO plc
  • Koninklijke Philips N.V.
1. Market Introduction
1.1 Market Definition
1.2 Market Segmentation
1.3 Assumption

2. Research Methodology
2.1 Research Objective
2.2 Research Process
2.3 Secondary Research
2.4 Market Size Estimation
2.5 Primary Research
2.5.1 Service Providers
2.5.2 Component Manufacturers

3. Executive Summary - Global Digital Biomarker Market

4. Pathway to Regulatory Approval of Digital Biomarkers

5. Analysis of Market Dynamics
5.1 Drivers
5.2 Restraints
5.3 Opportunities
5.4 Trends

6. COVID-19 Impact Analysis on the Global Digital Biomarker Market

7. PORTER’S Five Forces Analysis on the Global Digital Biomarker Market

8. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples

9. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets

10. World Mobile Data Traffic by Deployment Mode & Traffic by Device

11. Current Challenges of Digital Biomarkers in Medical Settings

12. Global Digital Biomarker Market
12.1 Global Digital Biomarker Market Segmentation by:
12.1.1 System Component, 2019-2030F (in USD Million)
12.1.2 Therapeutic Area, 2019-2030F (in USD Million)
12.1.3 Application, 2019-2030F (in USD Million)
12.1.4 Development Status, 2019-2030F (in USD Million)
12.1.5 End User, 2019-2030F (in USD Million)

13. North America Digital Biomarker Market
13.1 North America Digital Biomarker Market Segmentation by:
13.1.1 System Component, 2019-2030F (in USD Million)
13.1.2 Therapeutic Area, 2019-2030F (in USD Million)
13.1.3 Application, 2019-2030F (in USD Million)
13.1.4 Development Status, 2019-2030F (in USD Million)
13.1.5 End User, 2019-2030F (in USD Million)
13.1.6 Country-wise, 2019-2030F (in USD Million)

14. Europe Digital Biomarker Market
14.1 Europe Digital Biomarker Market Segmentation by:
14.1.1 System Component, 2019-2030F (in USD Million)
14.1.2 Therapeutic Area, 2019-2030F (in USD Million)
14.1.3 Application, 2019-2030F (in USD Million)
14.1.4 Development Status, 2019-2030F (in USD Million)
14.1.5 End User, 2019-2030F (in USD Million)
14.1.6 Country-wise, 2019-2030F (in USD Million)

15. Asia Pacific Digital Biomarker Market
15.1 Asia Pacific Digital Biomarker Market Segmentation by:
15.1.1 System Component, 2019-2030F (in USD Million)
15.1.2 Therapeutic Area, 2019-2030F (in USD Million)
15.1.3 Application, 2019-2030F (in USD Million)
15.1.4 Development Status, 2019-2030F (in USD Million)
15.1.5 End User, 2019-2030F (in USD Million)
15.1.6 Country-wise, 2019-2030F (in USD Million)

16. Latin America Digital Biomarker Market
16.1 Latin America Digital Biomarker Market Segmentation by:
16.1.1 System Component, 2019-2030F (in USD Million)
16.1.2 Therapeutic Area, 2019-2030F (in USD Million)
16.1.3 Application, 2019-2030F (in USD Million)
16.1.4 Development Status, 2019-2030F (in USD Million)
16.1.5 End User, 2019-2030F (in USD Million)
16.1.6 Country-wise, 2019-2030F (in USD Million)

17. Middle East & Africa Digital Biomarker Market
17.1 Middle East & Africa Digital Biomarker Market Segmentation by:
17.1.1 System Component, 2019-2030F (in USD Million)
17.1.2 Therapeutic Area, 2019-2030F (in USD Million)
17.1.3 Application, 2019-2030F (in USD Million)
17.1.4 Development Status, 2019-2030F (in USD Million)
17.1.5 End User, 2019-2030F (in USD Million)
17.1.6 Country-wise, 2019-2030F (in USD Million)

18. Competitive Landscape
18.1 ActiGraph LLC
18.2 Akili Interactive Labs, Inc.
18.3 AliveCor, Inc.
18.4 Altoida, Inc.
18.5 Biogen Inc.
18.6 ConnectedLife Health Pte Ltd
18.7 Cambridge Cognition Ltd
18.8 Evidation Health, Inc.
18.9 Fitbit, Inc.
18.10 Happify, Inc.
18.11 Human API
18.12 GlaxoSmithKline plc
18.13 Huma
18.14 IXICO plc
18.15 Kinsa Inc.
18.16 Koneksa
18.17 Medical Care Corporation
18.18 Mindstrong Health
18.19 Koninklijke Philips N.V.
18.20 Neurotrack Technologies, Inc.
18.21 Novartis AG
18.22 ResMed
18.23 F. Hoffmann-La Roche Ltd
18.24 Winterlight Labs
18.25 Verily Life Sciences LLC
Note: Product cover images may vary from those shown
  • ActiGraph LLC
  • Akili Interactive Labs Inc.
  • AliveCor Inc.
  • Altoida Inc.
  • Biogen Inc.
  • ConnectedLife Health Pte Ltd
  • Cambridge Cognition Ltd
  • Evidation Health Inc.
  • Fitbit Inc.
  • Happify Inc.
  • Human API
  • GlaxoSmithKline plc
  • Huma
  • IXICO plc
  • Kinsa Inc.
  • Koneksa
  • Medical Care Corporation
  • Mindstrong Health
  • Koninklijke Philips N.V.
  • Neurotrack Technologies Inc.
  • Novartis AG
  • ResMed
  • F. Hoffmann-La Roche Ltd
  • Winterlight Labs
  • Verily Life Sciences LLC
Note: Product cover images may vary from those shown